Latest 25 News in the Life Sciences Industry
GlobeNewswire
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
31 Jul 2026
GlobeNewswire
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21 Jul 2026
GlobeNewswire
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17 Jul 2026
GlobeNewswire
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
06 Jul 2026
GlobeNewswire
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
02 Jul 2026
GlobeNewswire
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
12 Jun 2026
GlobeNewswire
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
11 Jun 2026
GlobeNewswire
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
08 Jun 2026
GlobeNewswire
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
04 Jun 2026
GlobeNewswire
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
03 Jun 2026
GlobeNewswire
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
01 Jun 2026
GlobeNewswire
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
01 Jun 2026
GlobeNewswire
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
31 May 2026
GlobeNewswire
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
26 May 2026
GlobeNewswire
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
21 May 2026
GlobeNewswire
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
17 May 2026
GlobeNewswire
CJ Biomaterials Launches New Home Compostable all-PHA Extrusion Coating Resin for Paper Food Serviceware
14 May 2026
GlobeNewswire
CJ Biomaterials and Yuhan-Kimberly Launch World’s First Reusable Nonwoven Paper Towel Made with Amorphous PHA
07 May 2026
GlobeNewswire
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
07 May 2026
GlobeNewswire
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30 Apr 2026
GlobeNewswire
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
28 Apr 2026
GlobeNewswire
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27 Apr 2026
GlobeNewswire
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
24 Apr 2026
Latest News All News
Upcoming Events All Events
- October 2026
- Queensland: AusBiotech Invest
- Queensland: AusBiotech International Conference
- New York City: BioFuture 2026